-
公开(公告)号：US20230227449A1
公开(公告)日：2023-07-20
申请号：US18068407
申请日：2022-12-19
发明人： Andrew Simon Bell , Jérémy Besnard , Anthony Richard Bradley , Luke Green , Wolfgang Haap , Buelent Kocer , Andreas Kuglstatter , Xavier Lucas , Patrizio Mattei , Dmitry Mazunin , Hasane Ratni , Claus Riemer , Willem Paul Van Hoorn
IPC分类号： C07D471/04 , C07D405/04 , C07D519/00 , C07D401/04 , C07D239/95
CPC分类号： C07D471/04 , C07D405/04 , C07D519/00 , C07D401/04 , C07D239/95
摘要： The present invention provides compounds of formula I or II:
wherein X1, X3, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.-
公开(公告)号：US20230221300A1
公开(公告)日：2023-07-13
申请号：US17933447
申请日：2022-09-19
发明人： Stephen FOWLER , Na Hong QIU , Guojun CHEN
摘要： The present invention provides cell assay systems and its use in cell based assays.
-
93.发明公开公开(公告)号：US20230210887A1
公开(公告)日：2023-07-06
申请号：US18145791
申请日：2022-12-22
IPC分类号： A61K31/7125 , C12Q1/6883 , C12N15/113 , C12Q1/70 , A61P31/14 , A61K31/4745 , A61K31/519 , C07K16/40 , A61P31/20
CPC分类号： A61K31/7125 , C12Q1/6883 , C12N15/113 , C12Q1/706 , A61P31/14 , A61K31/4745 , A61K31/519 , C07K16/40 , C12N15/1137 , A61P31/20 , C07K2317/732 , C12N2310/14
摘要： The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis virus (HBV) infection, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a BV infection. The invention also provides for inhibitors of PAPD5 or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.
-
公开(公告)号：US20230210860A1
公开(公告)日：2023-07-06
申请号：US17818294
申请日：2022-08-08
发明人： Takeki UEHARA , Toru ISHIBASHI , Takao SHISHIDO , Keita FUKAO , Motoyasu OONISHI , Barry CLINCH , Jaspinder RANDHAWA
IPC分类号： A61K31/5383 , A61K31/215 , A61P31/16
CPC分类号： A61K31/5383 , A61K31/215 , A61P31/16
摘要： A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.
-
公开(公告)号：US20230203043A1
公开(公告)日：2023-06-29
申请号：US17976651
申请日：2022-10-28
发明人： Jean-Baptiste BLANC , Christian LERNER , Matthias NETTEKOVEN , Philippe PFLIEGER , Bernd PUELLMANN , Sébastien SCHMITT , Theodor STOLL , Song YANG , Chengang ZHOU
IPC分类号： C07D487/04 , C07D519/00
CPC分类号： C07D487/04 , C07D519/00
摘要： The invention provides novel imidazopyrazine derivatives having the general formula (I), or pharmaceutically acceptable salts thereof, wherein X and R3 to R9 are as described herein:
Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.-
公开(公告)号：US20230202990A1
公开(公告)日：2023-06-29
申请号：US18157285
申请日：2023-01-20
发明人： Cosimo DOLENTE , Guido GALLEY , Patrick SCHNIDER
IPC分类号： C07D249/08 , C07D213/643 , C07D241/18
CPC分类号： C07D249/08 , C07D213/643 , C07D241/18
摘要： The invention provides novel compounds having the general formula I
wherein R1, R2 and R3 are as defined herein, compositions including the compounds and methods of using the compounds as V1a receptor modulators for treatment of conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior, social anxiety disorder, post-traumatic stress disorder (PTSD), brain edema in stroke or traumatic brain injury, and phase shift sleep disorders such as jetlag-
公开(公告)号：US11685790B2
公开(公告)日：2023-06-27
申请号：US17399988
申请日：2021-08-11
发明人： Thomas Hofer , Maximiliane Koenig , Ekkehard Moessner , Jens Niewoehner , Tina Weinzierl , Laurent Lariviere
CPC分类号： C07K16/3069 , A61P35/00 , C07K16/2809 , C07K2317/31 , C07K2317/55 , C07K2317/565
摘要： The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
-
公开(公告)号：US20230197278A1
公开(公告)日：2023-06-22
申请号：US17860939
申请日：2022-07-08
摘要： Techniques are provided for predicting a risk of a subject experiencing a cytokine release syndrome of at least a threshold grade subsequent to receiving a treatment. The risk may be predicted based on (for example) a set of baseline characteristics, a risk-score generation model, an on-treatment cytokine level, and/or a treatment dosage. The risk may be used to generate an output corresponding to a recommendation as to whether to monitor the subject via in-patient monitoring.
-
公开(公告)号：US20230192795A1
公开(公告)日：2023-06-22
申请号：US17996338
申请日：2021-04-13
发明人： Laura Codarri Deak , Anne Freimoser-Grundschober , Christian Klein , Laura Lauener , Ekkehard Moessner , Cindy Schulenburg , Pablo Umaña , Eleni Maria Varypataki
CPC分类号： C07K14/5418 , A61P35/00 , C07K16/2818 , A61K2039/505
摘要： The present invention generally relates to mutant interleukin-7 polypeptides, immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-7 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the mutant interleukin-7 polypeptides or the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant interleukin-7 polypeptides, immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
-
公开(公告)号：US20230181712A1
公开(公告)日：2023-06-15
申请号：US17924645
申请日：2021-05-10
发明人： Pablo UMAÑA , Christian KLEIN , Christine TRUMPFHELLER , Valeria G. NICOLINI , Laura CODARRI DEAK , Scott LOUGHHEAD , Matthew BOOTY
IPC分类号： A61K39/12 , A61K47/68 , A61K35/17 , A61K39/39 , C12N15/117
CPC分类号： A61K39/12 , A61K47/6851 , A61K47/6813 , A61K35/17 , A61K39/39 , C12N15/117 , A61K2039/6006
摘要： The present application provides methods for stimulating an immune response in an individual comprising administering a composition of nucleated cells (e.g., PBMCs) comprising an intracellular exogenous antigen in conjunction with administering an immunoconjugate comprising a variant IL-2 polypeptide and a second polypeptide. The variant IL-2 polypeptide exhibits reduced affinity to the α-subunit of the IL-2 receptor. The second polypeptide targets a tumor cell or a T cell.
-
-
-
-
-
-
-
-
-
搜索结果
8129 条记录 (耗时 0.044 秒)
